 NEW YORK, Sept. 30, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its phase 2 CALLIPER trial of lead asset IMU-838, the companys selective oral DHODH inhibitor, in patients with progressive multiple sclerosis PMS. 